2017-25920. Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA or Agency) is withdrawing approval of 68 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

    DATES:

    Approval is withdrawn as of January 2, 2018.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

    Table 1

    Application No.DrugApplicant
    ANDA 040135Estropipate Tablets USP, 0.75 milligrams (mg), 1.5 mg, and 3 mgBarr Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 040755Carisoprodol Tablets USP, 350 mgSun Pharmaceutical Industries, Ltd., c/o Sun Pharmaceutical Industries, Inc., 270 Prospect Plains Rd., Cranbury, NJ 08512.
    Start Printed Page 56977
    ANDA 062588Gentamicin Sulfate in 0.9% Sodium Chloride Injection, Equivalent to (EQ) 1.2 mg base/milliliter (mL), EQ 1.4 mg base/mL, EQ 1.6 mg base/mL, EQ 1.8 mg base/mL, EQ 2 mg base/mL, EQ 60 mg base/100 mL, EQ 70 mg base/100 mL, EQ 80 mg base/100 mL, EQ 90 mg base/100 mL, and EQ 100 mg base/100 mLHospira, Inc., a Pfizer Company, 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.
    ANDA 062591Kefurox (cefuroxime) for Injection USP, EQ 750 mg base/vial, EQ 1.5 grams (g) base/vial, and EQ 7.5 g base/vialACS Dobfar S.p.A., c/o Interchem Corp., 120 Route 17 North, Paramus, NJ 07652.
    ANDA 062756Primaxin IV (imipenem and cilastatin) for Injection USP, 250 mg/vial; EQ 250 mg base/vial and 500 mg/vial; EQ 500 mg base/vialMerck Sharp & Dohme Corp., Subsidiary of Merck & Co., Inc., 1 Merck Dr., P.O. Box 100, Whitehouse Station, NJ 08889.
    ANDA 063207Cefazolin for Injection USP, EQ 1 g base/vialFacta Farmaceutici S.p.A., c/o Interchem Corp., 120 Route 17 North, Suite 115, Paramus, NJ 07652.
    ANDA 063209Cefazolin for Injection USP, EQ 10 g base/vial and EQ 20 g base/vial (Pharmacy Bulk Package)Do.
    ANDA 063214Cefazolin for Injection USP, EQ 500 mg base/vialDo.
    ANDA 063263Amikacin Sulfate Injection USP, EQ 50 mg base/mLHospira, Inc.
    ANDA 065268Ceftriaxone for Injection USP, EQ 1 g base/vial and EQ 2 g base/vialFacta Farmaceutici S.p.A.
    ANDA 065269Ceftriaxone for Injection USP, EQ 10 g base/vial (Pharmacy Bulk Package)Do.
    ANDA 065348Cefotaxime for Injection USP, EQ 10 g base/vial (Pharmacy Bulk Package)Cephazone Pharma, LLC, 250 E. Bonita Ave., Pomona, CA 91767.
    ANDA 065464Cefoxitin for Injection USP, EQ 10 g base/vial (Pharmacy Bulk Package)ACS Dobfar S.p.A.
    ANDA 065467Cefoxitin for Injection USP, EQ 1 g base/vial and EQ 2 g base/vialDo.
    ANDA 070048Cotrim D.S. (sulfamethoxazole and trimethoprim) Tablets USP, 800 mg/160 mgTeva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 070195Valproic Acid Capsules USP, 250 mgCatalent Pharma Solutions, LLC, 2725 Scherer Dr. North, St. Petersburg, FL 33716.
    ANDA 070513Tolazamide Tablets USP, 100 mgWatson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 070514Tolazamide Tablets USP, 250 mgDo.
    ANDA 071358Tolazamide Tablets USP, 250 mgSun Pharmaceutical Industries, Inc., 270 Prospect Plains Rd., Cranbury, NJ 08512.
    ANDA 071359Tolazamide Tablets USP, 500 mgDo.
    ANDA 071667Ibuprofen Tablets USP, 600 mgPliva, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 071668Ibuprofen Tablets USP, 800 mgDo.
    ANDA 071735Ibuprofen Tablets USP, 200 mgContract Pharmacal Corp., c/o SciRegs International Inc., 6333 Summercrest Dr., Columbia, MD 21045.
    ANDA 071773Ibuprofen Tablets USP, 200 mgPliva, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 073254Loperamide Hydrochloride (HCl) Tablets USP, 2 mgContract Pharmacal Corp.
    ANDA 074075Clemastine Fumarate Syrup, EQ 0.5 mg base/5 mLActavis Mid Atlantic, LLC, Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 074536Haloperidol Oral Solution USP, EQ 1 mg base/mLDo.
    ANDA 074782Ibuprofen Capsules, 200 mgContract Pharmacal Corp.
    ANDA 074789Naproxen Sodium Tablets USP, EQ 200 mg baseDo.
    ANDA 074931Ibuprofen Tablets USP, 200 mgDo.
    ANDA 074961Cimetidine Tablets USP, 200 mgDo.
    ANDA 074963Cimetidine Tablets USP, 200 mgDo.
    ANDA 075094Ranitidine Tablets USP, EQ 75 mg baseDo.
    ANDA 075588Ibuprofen and Pseudoephedrine HCl Tablets USP, 200 mg/30 mgDo.
    ANDA 077058Pantoprazole Sodium Delayed-Release Tablets USP, EQ 20 mg base and EQ 40 mg baseSun Pharmaceutical Industries, Ltd.
    ANDA 077172Ondansetron Injection USP, EQ 2 mg base/mLDo.
    ANDA 077329Octreotide Acetate Injection, EQ 0.05 mg base/mL, EQ 0.1 mg base/mL, and EQ 0.5 mg base/mLDo.
    ANDA 077330Octreotide Acetate Injection, EQ 0.2 mg base/mLDo.
    ANDA 077331Octreotide Acetate Injection, EQ 1 mg base/mLDo.
    ANDA 078108Sertraline HCl Tablets, EQ 25 mg base, EQ 50 mg base, and EQ 100 mg baseDo.
    ANDA 078478Torsemide Tablets, 5 mg, 10 mg, 20 mg, and 100 mgDo.
    ANDA 083000Folic Acid Tablets, 1 mgIvax Pharmaceutical USA, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 085549Reserpine, Hydralazine HCl, and Hydrochlorothiazide Tablets, 0.1 mg/25 mg/15 mgWatson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 086109Tolbutamide Tablets USP, 500 mgDo.
    ANDA 086577Trimethobenzamide HCl Injection, 100 mg/mLDo.
    Start Printed Page 56978
    ANDA 087191Triamcinolone Acetonide Lotion USP, 0.025%Alpharma U.S. Pharms, Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
    ANDA 087398Spironolactone and Hydrochlorothiazide Tablets USP, 25 mg/25 mgWatson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 088229Thioridazine HCl Oral Solution USP, 100 mg/mLActavis Mid Atlantic, LLC, Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 088563Thioridazine HCl Tablets USP, 50 mgWatson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 088567Thioridazine HCl Tablets USP, 25 mgDo.
    ANDA 088733Meclizine HCl Tablets, 25 mg (Chewable)Pliva, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 088869Thioridazine HCl Tablets USP, 150 mgWatson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
    ANDA 090800Quinapril Tablets USP, EQ 5 mg base, EQ 10 mg base, EQ 20 mg base, and EQ 40 mg baseSun Pharmaceutical Industries, Ltd.
    ANDA 091177Anastrozole Tablets, 1 mgDo.
    ANDA 091466Letrozole Tablets USP, 2.5 mgDo.
    ANDA 200486Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/0.035 mg, 0.75 mg/0.035 mg, and 1 mg/0.035 mgMylan Laboratories, Ltd., c/o Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504.
    ANDA 200488Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/0.035 mgDo.
    ANDA 200489Norethindrone and Ethinyl Estradiol Tablets USP, 1 mg/0.035 mgDo.
    ANDA 201250Vancomycin HCl for Injection USP, EQ 5 g base/vial and EQ 10 g base/vial (Pharmacy Bulk Package)Teva Pharmaceuticals USA, Inc.
    ANDA 201251Vancomycin HCl for Injection USP, EQ 500 mg base/vial and EQ 1 g base/vialDo.
    ANDA 201828Norgestrel and Ethinyl Estradiol Tablets USP, 0.3 mg/0.03 mgMylan Laboratories, Ltd.
    ANDA 202203Topotecan HCl for Injection, EQ 4 mg base/vialSun Pharmaceutical Industries, Ltd.
    ANDA 202746Zoledronic Acid Injection, EQ 4 mg base/5 mLSun Pharma Global FZE, c/o Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540.
    ANDA 202875Norgestrel and Ethinyl Estradiol Tablets USP, 0.5 mg/0.05 mgMylan Laboratories, Ltd.
    ANDA 203476Zolmitriptan Tablets, 2.5 mg and 5 mgSun Pharma Global FZE.
    ANDA 203685Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mgAjanta Pharma Ltd., c/o Ajanta Pharma USA, Inc., One Grande Commons, 440 US Highway 22 East, Suite 150, Bridgewater, NJ 08807.
    ANDA 203838Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine HCl Oral Solution, 5 mg/4 mg/60 mg per 5 mLTris Pharma, Inc., 2033 Route 130, Monmouth Junction, NJ 08852.
    ANDA 203839Hydrocodone Bitartrate and Pseudoephedrine HCl Oral Solution, 5 mg/60 mg per 5 mLDo.

    Therefore, approval of the applications listed in table 1 of this document, and all amendments and supplements thereto, is hereby withdrawn as of January 2, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

    Start Signature

    Dated: November 27, 2017.

    Leslie Kux,

    Associate Commissioner for Policy..

    End Signature End Supplemental Information

    [FR Doc. 2017-25920 Filed 11-30-17; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
12/01/2017
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2017-25920
Dates:
Approval is withdrawn as of January 2, 2018.
Pages:
56976-56978 (3 pages)
Docket Numbers:
Docket No. FDA-2017-N-6591
PDF File:
2017-25920.pdf